课题基金 / 基金详情

Impact of periconceptual vaginal microbiota on women's risk of preterm birth

Impact of periconceptual vaginal microbiota on women's risk of preterm birth
围孕期阴道微生物群对女性早产风险的影响
批准号:
9342979
负责人:
Raymond Scott McClelland
金额:
$54.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2021-07-31

项目摘要

项目成果

Raymond Scott McClelland的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Preterm birth occurs in an estimated 10% of pregnancies, causing high rates of morbidity and mortality in infants. This public health problem has led to domestic and international initiatives including the US Surgeon General's Conference on Preventing Preterm Birth and the Millennium Development Goals (Goal 4, Reduce Child Mortality). Spontaneous preterm birth (SPTB) accounts for 70-80% of preterm births, with the remainder being medically induced. Bacterial vaginosis (BV) is a common condition that has consistently been associated with SPTB. Many bacteria associated with BV remain difficult to detect using cultivation methods, but are easily detected using molecular methods. Despite the consistent association between BV and SPTB, treating BV during pregnancy has failed to reduce SPTB in numerous clinical trials, raising critical questions: Do key bacterial species mediate the risk of SPTB? Is treatment of BV during pregnancy too late to reduce SPTB? Our multidisciplinary team has been at the forefront in developing cutting-edge laboratory techniques and applying them in carefully conducted epidemiological studies to make important discoveries linking disruption of the vaginal microbiota to adverse reproductive health outcomes. In this proposal, we will test the overarching hypothesis that high-risk vaginal bacterial species present near the time of conception colonize the uterine cavity, causing sub-clinical inflammation, and leading to SPTB. We will leverage access to facilities, highly trained staff, and a population of Kenyan women attending preconception clinics supported with US CDC and NIH funding, to make this unique case-cohort study possible. Aim 1 will employ broad-range 16S ribosomal RNA gene polymerase chain reaction (PCR) and deep sequencing to compare vaginal bacterial community structure, diversity, richness, and the presence of key species near conception, in women with SPTB vs. term delivery. Aim 2 will use highly sensitive quantitative PCR (qPCR) assays to compare the presence and concentrations of key vaginal bacterial species near conception in women with SPTB vs. term birth, validating or refuting preliminary associations observed in Aim 1. Aim 3 will utilize fetal membrane and umbilical cord samples collected at delivery, combining species-specific qPCR assays and histological examination, to determine whether vaginal bacteria associated with SPTB in Aims 1 and 2 ascend to the upper genital tract and cause inflammation. In parallel, we will examine associations between key vaginal bacterial species during pregnancy and SPTB, allowing us to directly compare the risk of SPTB associated with vaginal bacteria identified in the peri-conception period vs. during pregnancy. Identification of strong relationships between bacterial species and communities present close to the time of conception and SPTB is expected to shift our paradigm for understanding how vaginal microbiota influences women's risk of SPTB. These data could inform development of targeted interventions based on elimination of high-risk species and promotion of low-risk vaginal bacterial communities in women planning a pregnancy, particularly after prior SPTB.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
University of Washington Vaccine and Treatment Evaluation Unit - DMID 21-0012
  • 批准号:
    10410301
  • 项目类别:
  • 资助金额:
    $125.93万
  • 财政年份:
    2021
  • 负责人:
    Raymond Scott McClelland
  • 依托单位:
University of Washington Vaccine and Treatment Evaluation Unit
  • 批准号:
    10462171
  • 项目类别:
  • 资助金额:
    $42.76万
  • 财政年份:
    2021
  • 负责人:
    Raymond Scott McClelland
  • 依托单位:
University of Washington Vaccine and Treatment Evaluation Unit
  • 批准号:
    10467264
  • 项目类别:
  • 资助金额:
    $251.67万
  • 财政年份:
    2021
  • 负责人:
    Raymond Scott McClelland
  • 依托单位:
University of Washington Vaccine and Treatment Evaluation Unit -- DMID 20-0034
  • 批准号:
    10360371
  • 项目类别:
  • 资助金额:
    $73.41万
  • 财政年份:
    2021
  • 负责人:
    Raymond Scott McClelland
  • 依托单位:
海外基金